Loading video...

Video Failed to Load

Go Home

ImmunityBio confirmed statistical power in our pivotal randomized trial evaluating ANKTIVA® + BCG versus BCG alone in BCG-naïve NMIBC, supporting the ability to detect clinically meaningful differences between treatment arms. This milestone builds on prior interim findings showing improved durability of complete response with ANKTIVA + BCG, reinforcing continued...

ImmunityBio's profile picture

ImmunityBio, Inc.

19,809 subscribers

11,424 views • 4 months ago •via X (Twitter)

LIVE

Anya Rossi• Live Now

Private livecam show

0 Comments

No comments available

Comments from the original post will appear here

Related Videos

We are pleased to announce positive topline event-free survival results from our Phase 3 study in patients with BCG-naïve, high-risk non-muscle invasive #BladderCancer (NMIBC). Learn more:
0:14

We are pleased to announce positive topline event-free survival results from our Phase 3 study in patients with BCG-naïve, high-risk non-muscle invasive #BladderCancer (NMIBC). Learn more:

Pfizer Inc.

11,658 views • 1 year ago

Today, the Saudi Food and Drug Authority (SFDA) granted accelerated approval of ANKTIVA® for use in combination with immune checkpoint inhibitors for adult patients with metastatic NSCLC whose disease has progressed following standard-of-care therapy. This marks the first approval anywhere in the world for ANKTIVA in this indication. Learn more:
0:14

Today, the Saudi Food and Drug Authority (SFDA) granted accelerated approval of ANKTIVA® for use in combination with immune checkpoint inhibitors for adult patients with metastatic NSCLC whose disease has progressed following standard-of-care therapy. This marks the first approval anywhere in the world for ANKTIVA in this indication. Learn more:

ImmunityBio, Inc.

14,278 views • 7 months ago

ImmunityBio reported that median overall survival has not yet been reached in patients with recurrent or progressive glioblastoma treated with a chemo-free ANKTIVA® + CAR-NK-based regimen. As recent American Cancer Society data shows that brain cancer is now the third leading cause of cancer-related death among adults ages 20–49, these findings underscore the urgency of continued innovation in this disease. Read more:
0:14

ImmunityBio reported that median overall survival has not yet been reached in patients with recurrent or progressive glioblastoma treated with a chemo-free ANKTIVA® + CAR-NK-based regimen. As recent American Cancer Society data shows that brain cancer is now the third leading cause of cancer-related death among adults ages 20–49, these findings underscore the urgency of continued innovation in this disease. Read more:

ImmunityBio, Inc.

107,673 views • 7 months ago

We’ve reported ~700% year-over-year revenue growth, expanded ANKTIVA® authorizations in 33 countries, and continued progress in lung cancer. With additional label expansion plans and global commercialization efforts underway, we remain focused on broadening patient access worldwide. Read more:
0:14

We’ve reported ~700% year-over-year revenue growth, expanded ANKTIVA® authorizations in 33 countries, and continued progress in lung cancer. With additional label expansion plans and global commercialization efforts underway, we remain focused on broadening patient access worldwide. Read more:

ImmunityBio, Inc.

58,491 views • 5 months ago

A Mayo Clinic-developed artificial intelligence (AI) model can help specialists detect pancreatic cancer on routine abdominal CT scans up to three years before clinical diagnosis. It identifies subtle signs of disease before tumors are visible, when curative treatment may still be possible. The findings, published in Gut, mark a milestone in Mayo Clinic's multiyear research effort to enable earlier detection of one of the deadliest cancers. Learn more:
0:12

A Mayo Clinic-developed artificial intelligence (AI) model can help specialists detect pancreatic cancer on routine abdominal CT scans up to three years before clinical diagnosis. It identifies subtle signs of disease before tumors are visible, when curative treatment may still be possible. The findings, published in Gut, mark a milestone in Mayo Clinic's multiyear research effort to enable earlier detection of one of the deadliest cancers. Learn more:

Mayo Clinic

2,135,430 views • 3 months ago

After so many yearsss we've seen this again 😌🤭 waaaaa!! What is this behavior Beccaaa? 🤭 Closer and wide view.. THAILAND BCG FREENBECKY #THLocalBCGxFreenBecky #FreenBecky #srchafreen #Beckysangels
0:11

After so many yearsss we've seen this again 😌🤭 waaaaa!! What is this behavior Beccaaa? 🤭 Closer and wide view.. THAILAND BCG FREENBECKY #THLocalBCGxFreenBecky #FreenBecky #srchafreen #Beckysangels

Angel's GirlFreen ⭐

39,304 views • 2 years ago

At ImmunityBio, our pipeline continues to expand with chemotherapy-free approaches designed to harness the power of one's own immune system. We have launched ResQ215B, a Phase 2 clinical study evaluating a novel chemotherapy-free and lymphodepletion-free combination immunotherapy in patients with indolent B-cell non-Hodgkin lymphoma (iNHL), including Waldenström’s Macroglobulinemia. Learn more:
0:14

At ImmunityBio, our pipeline continues to expand with chemotherapy-free approaches designed to harness the power of one's own immune system. We have launched ResQ215B, a Phase 2 clinical study evaluating a novel chemotherapy-free and lymphodepletion-free combination immunotherapy in patients with indolent B-cell non-Hodgkin lymphoma (iNHL), including Waldenström’s Macroglobulinemia. Learn more:

ImmunityBio, Inc.

62,193 views • 6 months ago

Pleased to announce the first patient has been dosed in our Phase 1 clinical trial, evaluating our lead candidate for optic neuropathies. This marks a key milestone as our epigenetic restoration therapy enters the clinic for glaucoma & NAION. Read more:
0:17

Pleased to announce the first patient has been dosed in our Phase 1 clinical trial, evaluating our lead candidate for optic neuropathies. This marks a key milestone as our epigenetic restoration therapy enters the clinic for glaucoma & NAION. Read more:

Life Biosciences

11,683 views • 2 months ago

In 2023 we recycled 938.8 million kg of waste globally instead of sending it to landfill. Learn more about our continued efforts on The #RoadToBetter.
0:14

In 2023 we recycled 938.8 million kg of waste globally instead of sending it to landfill. Learn more about our continued efforts on The #RoadToBetter.

Ford Motor Company

19,317 views • 2 years ago

Additional video has emerged from the Shatura Power Plant attack. Since earlier footage of the strike and resulting fire was recorded in the dark, this appears to have been a continued attack. Despite attempts to stop the drone with small arms, it successfully reached its target
0:12

Additional video has emerged from the Shatura Power Plant attack. Since earlier footage of the strike and resulting fire was recorded in the dark, this appears to have been a continued attack. Despite attempts to stop the drone with small arms, it successfully reached its target

Tatarigami_UA

184,662 views • 9 months ago

We’re excited to announce the upcoming launch of our $UOMI Public Sale, a significant milestone in our mission to bring true AI Agents on-chain and expand our community. 🚀 As part of this journey, we’re thrilled to reveal Poolz Finance as one of the first launchpad partners supporting the Public Sale! This partnership represents a pivotal step in making our vision accessible to a broader audience. Stay tuned for more updates as we unveil additional launchpads and partners. The $UOMI Public Sale is coming soon.
0:12

We’re excited to announce the upcoming launch of our $UOMI Public Sale, a significant milestone in our mission to bring true AI Agents on-chain and expand our community. 🚀 As part of this journey, we’re thrilled to reveal Poolz Finance as one of the first launchpad partners supporting the Public Sale! This partnership represents a pivotal step in making our vision accessible to a broader audience. Stay tuned for more updates as we unveil additional launchpads and partners. The $UOMI Public Sale is coming soon.

Uomi

24,674 views • 1 year ago

#Announcement 📣: Our tissue-informed circulating tumor DNA monitoring test is now available to all physicians in the US seeking personalized monitoring of their patients' response to treatment. More on this #Launch news:
0:14

#Announcement 📣: Our tissue-informed circulating tumor DNA monitoring test is now available to all physicians in the US seeking personalized monitoring of their patients' response to treatment. More on this #Launch news:

Foundation Medicine

678,416 views • 2 years ago

UNHCR has been present in Venezuela for more than 35 years. Now, in one of the times of greatest need, our teams are still on the ground. We’re supporting the protection response and working with authorities and partners to reach the most vulnerable. Donate to help.
0:10

UNHCR has been present in Venezuela for more than 35 years. Now, in one of the times of greatest need, our teams are still on the ground. We’re supporting the protection response and working with authorities and partners to reach the most vulnerable. Donate to help.

UNHCR, the UN Refugee Agency

10,766 views • 28 days ago

With World Health Organization (WHO)'s support, Ministry of Health- Uganda has started a vaccine trial against #Ebola Sudan virus today. The trial will enroll contacts of people with the disease, and contacts of the contacts. This vaccination trial was initiated with record speed, only three days since the outbreak was declared, while ensuring full compliance with international and national regulatory and ethical requirements. It is also the first trial to assess the clinical efficacy of a vaccine against Ebola Sudan virus disease. This trial demonstrates the importance of investing in R&D for vaccines and treatments and outbreak response preparedness, as well as partnerships. We thank Makerere University University and UVRI for their leadership, as well as Africa CDC, CEPI, EU HERA and IDRC | CRDI for their collaboration on this lifesaving effort. WHO will continue supporting the government in a comprehensive response to bring the outbreak under control.
0:19

With World Health Organization (WHO)'s support, Ministry of Health- Uganda has started a vaccine trial against #Ebola Sudan virus today. The trial will enroll contacts of people with the disease, and contacts of the contacts. This vaccination trial was initiated with record speed, only three days since the outbreak was declared, while ensuring full compliance with international and national regulatory and ethical requirements. It is also the first trial to assess the clinical efficacy of a vaccine against Ebola Sudan virus disease. This trial demonstrates the importance of investing in R&D for vaccines and treatments and outbreak response preparedness, as well as partnerships. We thank Makerere University University and UVRI for their leadership, as well as Africa CDC, CEPI, EU HERA and IDRC | CRDI for their collaboration on this lifesaving effort. WHO will continue supporting the government in a comprehensive response to bring the outbreak under control.

Tedros Adhanom Ghebreyesus

63,379 views • 1 year ago

🏀 Learn how to dominate the court with three of the best MyPlayer Builds in NBA 2K23. Our latest GG Guide breaks it down:
0:10

🏀 Learn how to dominate the court with three of the best MyPlayer Builds in NBA 2K23. Our latest GG Guide breaks it down:

PlayStation

871,401 views • 3 years ago

We are pleased to announce that #FDA has cleared our IND application for PM359 for the treatment of chronic granulomatous disease (CGD), enabling Prime to initiate its Phase 1/2 clinical trial in the US. Details: $PRME
0:12

We are pleased to announce that #FDA has cleared our IND application for PM359 for the treatment of chronic granulomatous disease (CGD), enabling Prime to initiate its Phase 1/2 clinical trial in the US. Details: $PRME

Prime Medicine

140,817 views • 2 years ago

Chiarot, Seider have some words with Eriksson Ek in response to this hit on Kane earlier on. #LGRW
0:13

Chiarot, Seider have some words with Eriksson Ek in response to this hit on Kane earlier on. #LGRW

Ryan Hana

54,663 views • 7 months ago

Separation confirmed! ✅ The SpaceX rocket has demonstrated its ability to withstand the extreme conditions of launch. Our next big milestone will be to acquire #MissionToPsyche's signal and confirm the spacecraft is in good health, which could take up to 2 hours.
0:16

Separation confirmed! ✅ The SpaceX rocket has demonstrated its ability to withstand the extreme conditions of launch. Our next big milestone will be to acquire #MissionToPsyche's signal and confirm the spacecraft is in good health, which could take up to 2 hours.

NASA JPL

5,888,426 views • 2 years ago

Peripheral artery disease is seen in 30% of people with diabetes over the age of 50.1 Learn more during ACC Congress 👇
0:20

Peripheral artery disease is seen in 30% of people with diabetes over the age of 50.1 Learn more during ACC Congress 👇

Novo Nordisk Live

4,955,314 views • 2 months ago